EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Urinary Inflammatory and Oxidative Stress Biomarkers as Indicators for the Clinical Management of Benign Prostatic Hyperplasia

Yuan-Hong Jiang iD, Jimmy Lee, Hann-Chorng Kuo iD, Ya-Hui Wu

International Journal of Molecular Sciences · 06.07.2025 · 26 (13) · 6516

DOI: 10.3390/ijms26136516 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.07.2025. Verfasst von Yuan-Hong Jiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 97004, Taiwan. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Biomarkers, Oxidative Stress, Inflammation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology (Taiwan).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oxidative stress and hypoxia-induced inflammation contribute to benign prostatic hyperplasia (BPH) progression. This study investigated the roles of urinary inflammatory and oxidative stress biomarkers in BPH patients. This prospective study enrolled 62 clinical BPH patients (33 treated medically, 29 surgically) and 20 controls. Symptom scores, uroflowmetry, and urinary biomarker levels were assessed at baseline and three months post-treatment. Before treatment, BPH patients exhibited elevated urinary levels of total antioxidant capacity (TAC), PGE2, IL-1β, and IL-6. Post-treatment, successful outcomes were reported in 63.6% of the medical treatment group and 86.2% of the surgical treatment group, with improvements in symptom scores and urinary flow rate, along with reductions in urinary 8-isoprostane, TAC, and IL-1β. Prior to treatment, voiding efficiency (VE) was negatively correlated with urinary IL-1β, IL-6, and IL-8 levels, while bladder wall thickness was positively correlated with TAC. After treatment, changes in VE were negatively correlated with changes in IL-1β, and changes in post-void residual urine were positively correlated with changes in IL-1β, IL-6, IL-8, and TNF-α. Urinary inflammatory and oxidative stress biomarkers may serve as non-invasive indicators of disease severity and treatment response in clinical BPH. Their significant correlations with clinical improvements underscore their potential utility in monitoring treatment efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic HyperplasiaBiomarkersOxidative StressInflammationHumansMaleAgedMiddle AgedProspective StudiesInterleukin-6Dinoprost

Stichwörter der Autor:innen

BPHinflammatory cytokineoxidative stressurinary biomarker

Substanzen

BiomarkersInterleukin-6Dinoprost

Autor:innen und Institutionen

  • Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 97004, Taiwan.
  • Department of Urology, School of Medicine, Tzu Chi University, Hualien 97004, Taiwan.
  • Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei 10051, Taiwan.
  • Pathology Department, National Taiwan University Hospital, Taipei 10051, Taiwan.

ORCID-Profile: Yuan-Hong Jiang, Hann-Chorng Kuo

Förderung

  • Ministry of Science and Technology (Taiwan)

Zitieren

APA

Jiang, Y. H., Lee, J., Kuo, H. C., & Wu, Y. H. (2025). Urinary Inflammatory and Oxidative Stress Biomarkers as Indicators for the Clinical Management of Benign Prostatic Hyperplasia. International Journal of Molecular Sciences, 26(13), 6516. https://doi.org/10.3390/ijms26136516

Vancouver

Jiang YH, Lee J, Kuo HC, Wu YH. Urinary Inflammatory and Oxidative Stress Biomarkers as Indicators for the Clinical Management of Benign Prostatic Hyperplasia. International Journal of Molecular Sciences. 2025;26(13):6516. doi:10.3390/ijms26136516

BibTeX
@article{Jiang2025,
  author = {Jiang, Yuan-Hong and Lee, Jimmy and Kuo, Hann-Chorng and Wu, Ya-Hui},
  title = {Urinary Inflammatory and Oxidative Stress Biomarkers as Indicators for the Clinical Management of Benign Prostatic Hyperplasia},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {13},
  pages = {6516},
  doi = {10.3390/ijms26136516}
}
Kostenlos starten →